WASHINGTON - The popular painkillers Celebrex and Bextra are likely to stay on the market, and Vioxx may rejoin them, now that government advisers have concluded their benefits outweigh their risks.... ...
Note: this page has been archived under Muzi Premium Version and is only available to premium members. Please use the Premium Personal Password (PPP) to log in.